Literature DB >> 16969683

Differential involvement of the endocannabinoid system in short- and long-term expression of incentive learning supported by nicotine in rats.

Benoît Forget1, Sandrine Barthélémy, Françoise Saurini, Michel Hamon, Marie-Hélène Thiébot.   

Abstract

RATIONALE: We previously reported that the CB1 cannabinoid receptor antagonist, rimonabant, impaired the acquisition and the short-term (24 h), but not long-term (3 weeks), expression of conditioned place preference (CPP) induced by nicotine in rats.
OBJECTIVE: To assess the time interval of efficacy of a single pretest injection of rimonabant to abolish nicotine-CPP, and the effects of chronic CB1 receptor blockade on long-term expression of nicotine-CPP.
MATERIALS AND METHODS: Wistar rats were conditioned to nicotine (0.06 mg/kg, subcutaneous) using an unbiased one-compartment procedure. Two test sessions were conducted 24 h (without injection) and 1, 2, or 3 weeks later. Rimonabant (3 mg/kg, intraperitoneal) or vehicle was administered daily between the two test sessions. In addition, the CB1-stimulated [(35)S]GTP-gamma-S binding was assessed in rats from the 3-week experiment.
RESULTS: The capacity of a single injection of rimonabant (3 mg/kg, 30 min pretest) to block the expression of nicotine-CPP disappeared within 1 week after conditioning. Daily administrations of rimonabant for 6, 13, or 20 days post-acquisition did not impair nicotine-CPP but allowed an additional pretest injection of rimonabant to retain its capacity to abolish long-term expression of nicotine-CPP. The CB1 receptor-mediated G-protein signaling was not altered in various brain areas of rats given rimonabant for 3 weeks.
CONCLUSIONS: The endocannabinoid system is essential to the expression of nicotine-CPP during less than 1 week after conditioning but not later. However, endocannabinoid-dependent mechanisms are critically involved in the development of the neuroadaptive changes responsible for the shift from CB1-dependent to CB1-independent expression of nicotine incentive learning.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16969683     DOI: 10.1007/s00213-006-0525-x

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  47 in total

1.  Functional interaction between opioid and cannabinoid receptors in drug self-administration.

Authors:  M Navarro; M R Carrera; W Fratta; O Valverde; G Cossu; L Fattore; J A Chowen; R Gomez; I del Arco; M A Villanua; R Maldonado; G F Koob; F Rodriguez de Fonseca
Journal:  J Neurosci       Date:  2001-07-15       Impact factor: 6.167

2.  Involvement of central cannabinoid (CB1) receptors in the establishment of place conditioning in rats.

Authors:  F Chaperon; P Soubrié; A J Puech; M H Thiébot
Journal:  Psychopharmacology (Berl)       Date:  1998-02       Impact factor: 4.530

3.  A cannabinoid mechanism in relapse to cocaine seeking.

Authors:  T J De Vries; Y Shaham; J R Homberg; H Crombag; K Schuurman; J Dieben; L J Vanderschuren; A N Schoffelmeer
Journal:  Nat Med       Date:  2001-10       Impact factor: 53.440

Review 4.  Beyond the reward hypothesis: alternative functions of nucleus accumbens dopamine.

Authors:  J D Salamone; M Correa; S M Mingote; S M Weber
Journal:  Curr Opin Pharmacol       Date:  2005-02       Impact factor: 5.547

5.  Lack of CB1 cannabinoid receptors modifies nicotine behavioural responses, but not nicotine abstinence.

Authors:  A Castañé; E Valjent; C Ledent; M Parmentier; R Maldonado; O Valverde
Journal:  Neuropharmacology       Date:  2002-10       Impact factor: 5.250

6.  Cannabinoid modulation of the reinforcing and motivational properties of heroin and heroin-associated cues in rats.

Authors:  Taco J De Vries; Judith R Homberg; Rob Binnekade; Halfdan Raasø; Anton N M Schoffelmeer
Journal:  Psychopharmacology (Berl)       Date:  2003-04-01       Impact factor: 4.530

7.  Cannabinoid CB1 receptors are involved in motivational effects of nicotine in rats.

Authors:  Benoît Forget; Michel Hamon; Marie-Hélène Thiébot
Journal:  Psychopharmacology (Berl)       Date:  2005-09-29       Impact factor: 4.530

8.  Rimonabant, a CB1 antagonist, blocks nicotine-conditioned place preferences.

Authors:  Bernard Le Foll; Steven R Goldberg
Journal:  Neuroreport       Date:  2004-09-15       Impact factor: 1.837

Review 9.  The endocannabinoid system in the basal ganglia and in the mesolimbic reward system: implications for neurological and psychiatric disorders.

Authors:  Mario van der Stelt; Vincenzo Di Marzo
Journal:  Eur J Pharmacol       Date:  2003-11-07       Impact factor: 4.432

10.  Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study.

Authors:  M Herkenham; A B Lynn; M R Johnson; L S Melvin; B R de Costa; K C Rice
Journal:  J Neurosci       Date:  1991-02       Impact factor: 6.167

View more
  10 in total

Review 1.  [Future medications for tobacco and cannabis dependence].

Authors:  Bernard Le Foll; Zuzana Justinova; Gianlugi Tanda; Steven R Goldberg
Journal:  Bull Acad Natl Med       Date:  2008-01       Impact factor: 0.144

Review 2.  Endocannabinoid-mediated synaptic plasticity and addiction-related behavior.

Authors:  Nimish Sidhpura; Loren H Parsons
Journal:  Neuropharmacology       Date:  2011-06-12       Impact factor: 5.250

Review 3.  Endocannabinoid influence in drug reinforcement, dependence and addiction-related behaviors.

Authors:  Antonia Serrano; Loren H Parsons
Journal:  Pharmacol Ther       Date:  2011-07-18       Impact factor: 12.310

Review 4.  Effects of nicotine in experimental animals and humans: an update on addictive properties.

Authors:  Bernard Le Foll; Steven R Goldberg
Journal:  Handb Exp Pharmacol       Date:  2009

5.  Rimonabant blocks the expression but not the development of locomotor sensitization to nicotine in rats.

Authors:  John E Kelsey; Siena Calabro
Journal:  Psychopharmacology (Berl)       Date:  2007-09-06       Impact factor: 4.530

6.  Intravenous nicotine conditions a place preference in rats using an unbiased design.

Authors:  Jamie L Wilkinson; Rick A Bevins
Journal:  Pharmacol Biochem Behav       Date:  2007-09-01       Impact factor: 3.533

Review 7.  Blocking cannabinoid CB1 receptors for the treatment of nicotine dependence: insights from pre-clinical and clinical studies.

Authors:  Bernard Le Foll; Benoit Forget; Henri-Jean Aubin; Steven R Goldberg
Journal:  Addict Biol       Date:  2008-06       Impact factor: 4.280

8.  Involvement of alpha1-adrenoceptors in conditioned place preference supported by nicotine in rats.

Authors:  Benoît Forget; Michel Hamon; Marie-Hélène Thiébot
Journal:  Psychopharmacology (Berl)       Date:  2009-05-23       Impact factor: 4.530

Review 9.  Endocannabinoid system involvement in brain reward processes related to drug abuse.

Authors:  Marcello Solinas; Sevil Yasar; Steven R Goldberg
Journal:  Pharmacol Res       Date:  2007-09-08       Impact factor: 7.658

Review 10.  New Insights in the Involvement of the Endocannabinoid System and Natural Cannabinoids in Nicotine Dependence.

Authors:  Rocio Saravia; Marc Ten-Blanco; Inmaculada Pereda-Pérez; Fernando Berrendero
Journal:  Int J Mol Sci       Date:  2021-12-10       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.